Social Forces to Improve Statin Adherence (Study A)
Primary Purpose
Medication Adherence, High Blood Pressure, Diabetes
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Medication Adherence Partner
Electronic pill bottle
Sponsored by

About this trial
This is an interventional treatment trial for Medication Adherence focused on measuring Medication Adherence, High Blood Pressure, Diabetes, Statins
Eligibility Criteria
Inclusion Criteria:
- The subject is Humana insured
- The subject is an English speaking adult
- Age range ≥18 years
- The subject has diagnosis with diabetes for ≥12 months
- The subject has an MPR <70% to a statin medication
- Subject denies side-effects to their statin medication
- The subject identified a person who agreed to serve as their MAP
Exclusion Criteria:
- The subject is <18 years old
- The subject is considered part of a vulnerable population (is a prisoner, a cognitively impaired person, or a pregnant woman)
- On statin combination medication
- The subject does not identify an individual who agrees to serve as their MAP
- The subject reports a clinically important side effect to the statin medication or active liver disease:
Sites / Locations
- University of Pennsylvania Perelman School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Other
Arm Label
MAP Daily Notification
MAP Weekly Notification
MAP Missed Doses
Usual Care
Arm Description
The subject's MAP receives daily notification about whether subject took statin.
The subject's MAP receives weekly about how often the subject took statin during previous week.
The subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin.
Usual care with GlowCap.
Outcomes
Primary Outcome Measures
Statin Adherence
The primary outcome will be the percent of statin doses taken during the study as measured by the GlowCaps.
Secondary Outcome Measures
Morisky Medication Adherence Scale (MMAS)
The secondary outcome will be subjects' self-reports medication adherence. Morisky et al. developed this 8-item MMAS (MMAS-8) in 2008. The first seven items are Yes/No responses while the last item is a 5-point Likert response. The scoring scheme is: "Yes" = 0 and "No" = 1 (and "0" = 0 and "1-4" = 1 for Likert question). The items are summed to give a range of scores from 0 to 8. Respondents' summed score get grouped as follows: "0" = High Adherence; "1-2" = Medium Adherence; "3-8" = Low Adherence.
Full Information
NCT ID
NCT02018809
First Posted
December 17, 2013
Last Updated
August 15, 2017
Sponsor
University of Pennsylvania
Collaborators
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT02018809
Brief Title
Social Forces to Improve Statin Adherence (Study A)
Official Title
Using Social Support To Improve Medication Adherence In Statin Users With Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania
Collaborators
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To assess the effectiveness of reporting statin adherence patterns to a Medication Adherence Partner (MAP) in improving the outcome of statin adherence versus usual care as measured by an electronic pill bottle.
Hypothesis: Subjects with a MAP receiving daily adherence feedback will have the highest statin adherence of any arm, as measured by pill bottle data.
Detailed Description
We propose to complete a randomized controlled trial (RCT) of 200 subjects with medication treated diabetes and evidence of poor adherence to a statin medication (<70% medication possession ratio determined through pharmacy records; no combination meds). Study subjects will use an electronic pill bottle (GlowCap) to store their statin medication. Study subjects will identify potential Medication Adherence Partners (MAPs) who can receive information about their adherence patterns at enrollment. For the 90-day trial, subjects will be randomized to: 1) the subject's MAP receives daily notification about whether subject took statin; 2) the subject's MAP receives weekly about how often the subject took statin during previous week; 3) the subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin; and 4) usual care (GlowCaps without any notifications). The primary outcome will be the percent of statin doses taken during the study as measured by the GlowCaps. The secondary outcome will be subjects' statin medication possession ratio (MPR) during the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Medication Adherence, High Blood Pressure, Diabetes
Keywords
Medication Adherence, High Blood Pressure, Diabetes, Statins
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MAP Daily Notification
Arm Type
Experimental
Arm Description
The subject's MAP receives daily notification about whether subject took statin.
Arm Title
MAP Weekly Notification
Arm Type
Experimental
Arm Description
The subject's MAP receives weekly about how often the subject took statin during previous week.
Arm Title
MAP Missed Doses
Arm Type
Experimental
Arm Description
The subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin.
Arm Title
Usual Care
Arm Type
Other
Arm Description
Usual care with GlowCap.
Intervention Type
Behavioral
Intervention Name(s)
Medication Adherence Partner
Intervention Type
Device
Intervention Name(s)
Electronic pill bottle
Other Intervention Name(s)
Vitality GlowCap
Intervention Description
This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
Primary Outcome Measure Information:
Title
Statin Adherence
Description
The primary outcome will be the percent of statin doses taken during the study as measured by the GlowCaps.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Morisky Medication Adherence Scale (MMAS)
Description
The secondary outcome will be subjects' self-reports medication adherence. Morisky et al. developed this 8-item MMAS (MMAS-8) in 2008. The first seven items are Yes/No responses while the last item is a 5-point Likert response. The scoring scheme is: "Yes" = 0 and "No" = 1 (and "0" = 0 and "1-4" = 1 for Likert question). The items are summed to give a range of scores from 0 to 8. Respondents' summed score get grouped as follows: "0" = High Adherence; "1-2" = Medium Adherence; "3-8" = Low Adherence.
Time Frame
90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The subject is Humana insured
The subject is an English speaking adult
Age range ≥18 years
The subject has diagnosis with diabetes for ≥12 months
The subject has an MPR <70% to a statin medication
Subject denies side-effects to their statin medication
The subject identified a person who agreed to serve as their MAP
Exclusion Criteria:
The subject is <18 years old
The subject is considered part of a vulnerable population (is a prisoner, a cognitively impaired person, or a pregnant woman)
On statin combination medication
The subject does not identify an individual who agrees to serve as their MAP
The subject reports a clinically important side effect to the statin medication or active liver disease:
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter P Reese, MD, MSCE
Organizational Affiliation
UPenn PSOM
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Judd B Kessler, PhD
Organizational Affiliation
UPenn, Wharton
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kevin Volpp, MD, PhD
Organizational Affiliation
UPenn, PSOM
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania Perelman School of Medicine
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Social Forces to Improve Statin Adherence (Study A)
We'll reach out to this number within 24 hrs